ANIP Company Profile and Key Details

ANIP has shown mixed momentum, gaining 1.68% over the past week and -9.52% over the past quarter, though year-to-date performance is up 8.65%. Short-term trend indicators are mixed aligned (SMA20 -2.14%, SMA50 -4.22%, SMA200 -3.05%). The stock’s 14-day RSI is 43.66 (neutral), while the ATR of 2.63 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -22.46% below its high and over 42.61% above its low. Average 10-day trading volume of 318.76 thousand shares is in line with the 3-month average of 346.25 thousand, indicating normal recent market interest.

ANI Pharmaceuticals, Inc. has 22.73 million shares outstanding. The public float is 19.42 million shares, elevated short interest at 18.10% of float. This equals 3.37 million shares. The short ratio is 9.99 days. Institutional investors hold 116.86% of the float. Insiders own 5.53%. MERIDIAN VENTURE PARTNERS II LP holds 1.82 million shares, Shanmugam Muthusamy has 431.92 thousand shares and MARSHBANKS TRACY has 349.93 thousand shares. Over the past six months, insider transactions show net selling. They sold 138.40 thousand shares across 30 transactions.

ANI Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$55.94. This means the shares are trading below this model’s fair value.

Wall Street analysts project EPS growth of 26.22% annually over the next five years. The latest quarter delivered EPS of $2.05. The next quarter is forecast at $1.99. Next year's EPS is expected at -$3.76. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 6 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $124.00 to $77.00. The high target offers 50.07% upside. The low target suggests -6.81% downside. The mean target is $105.82. This offers 28.06% upside. ANI Pharmaceuticals, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 08, 2026, missed forecasts by 60.16%. The prior quarter beat by 17.09%. Over the last six quarters, Apple has recorded several small beats. These include 15.6% in February 28, 2025.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) closed at $77.17 USD, losing -$5.46 (-6.61%) from the previous close of $82.63. The stock is currently mid-range between its 52-week high and low $70.15 and $99.50. With a market capitalization of about $1.75 billion, ANI Pharmaceuticals, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.43). Key stats such as the average daily volume over the past year has been around 342.94 thousand shares, in line with its 52-week average. Headquartered in Baudette, MN, ANI Pharmaceuticals, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Nikhil Lalwani, the company employs approximately 970 people and listed since May 05, 2000. ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.

ANI Pharmaceuticals, Inc. trades at a P/E ratio of 20.03, slightly below the S&P 500 average, with a price-to-sales ratio of 2.03 and a price-to-book ratio of 3.06 trading at moderately above to book value. The P/FCF stands at 11.67, also above market averages.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shares are flat 8.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ANI Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of 20.03. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $79.29, suggesting -4.04% downside. Our AI forecast model points to short-term strength (0.93% over two weeks), a medium-term rise (21.61% over three months), and a longer-term gain (8.77% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that ANI Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.93%, with price expected at $83.40 by August 20, 2026, within a range of $80.98 to $85.86 3-Month Outlook: Projected rise of 21.61%, reaching $100.49 by November 04, 2026, with a range of $97.26 to $103.96. 1-Year Outlook: Projected gain of 8.77%, with price at $89.88 by August 06, 2027, within a range of $86.93 to $92.82.